- ECOG NHLBI-MDS– The National Myelodysplastic Syndromes (MDS) Study
- ECOG E1912– Randomized Phase III Study if Ibrutinib based Therapy versus Standard Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunothearpy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
- ECOG E3A06– Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Mulitple Myeloma.
- SWOG S1211– Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamathasone, and Lenalidomide with/or without Elotuzumab for Newly Diagnosed High Risk Multiple Myeloma (HRMM). (Temporarily Closed)
- SWOG S1304– Randomized Phase II Study Comparing Two Doses of Carfilzomib with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease. (Temporarily closed to accural)
- ECOG E1A11– Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Sympotomatic Multiple Myeloma (ENDURANCE).
- OSU 2010-C0126- Buckeye Surveillance, Contact, and Research for MGUS, Myeloma, and Amyloidosis
- Alliance A061202– Randomized Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy.